A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

J&J Seeks Emergency Use Authorization for its One-Shot COVID-19 Vaccine


Johnson & Johnson (J&J) has applied for an Emergency Use Authorization (EUA)  from the United States Food and Drug Administration (FDA) for its one-shot COVID-19 vaccine, which has shown 66% efficacy in preventing moderate to severe COVID-19 illness. The J&J vaccine may be a game changer in the arduous fight against the novel coronavirus due to the need for only one immunization and the fact that it can be stored at 34° to 46° F. The only COVID-19 vaccines currently available in the US require two shots and sub-zero storage. However, both the Pfizer and Moderna vaccines have higher rates of efficacy (95%) than the J&J immunization. The FDA, along with contracted outside experts, will meet on February 26 to make a decision on the EUA application. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy